| Year |
Citation |
Score |
| 2023 |
Lelos MJ, Murphy EM, Lindgren HS, Dunnett SB, Lane EL. Impaired cognitive and motor function are coincident with L-DOPA-induced dyskinesia in a model of Parkinson's disease. Scientific Reports. 13: 17697. PMID 37848479 DOI: 10.1038/s41598-023-44869-y |
0.446 |
|
| 2022 |
Batstone RT, Lindgren H, Allsup CM, Goralka LA, Riley AB, Grillo MA, Marshall-Colon A, Heath KD. Genome-Wide Association Studies across Environmental and Genetic Contexts Reveal Complex Genetic Architecture of Symbiotic Extended Phenotypes. Mbio. e0182322. PMID 36286519 DOI: 10.1128/mbio.01823-22 |
0.626 |
|
| 2015 |
Cenci MA, Francardo V, O'Sullivan SS, Lindgren HS. Rodent models of impulsive-compulsive behaviors in Parkinson's disease: How far have we reached? Neurobiology of Disease. 82: 561-73. PMID 26325219 DOI: 10.1016/J.Nbd.2015.08.026 |
0.722 |
|
| 2014 |
Francardo V, Iderberg H, Lindgren H, Angela Cenci M. Rodent Models of Treatment-Related Complications in Parkinson Disease Movement Disorders: Genetics and Models: Second Edition. 373-386. DOI: 10.1016/B978-0-12-405195-9.00022-6 |
0.708 |
|
| 2013 |
Rylander D, Lindgren HS. The serotonergic component in Parkinson's disease symptoms and therapy side-effects Serotonergic Systems: Evolution, Functions and Roles in Disease. 107-129. |
0.722 |
|
| 2012 |
Lindgren HS, Lelos MJ, Dunnett SB. Do α-synuclein vector injections provide a better model of Parkinson's disease than the classic 6-hydroxydopamine model? Experimental Neurology. 237: 36-42. PMID 22727767 DOI: 10.1016/j.expneurol.2012.05.022 |
0.386 |
|
| 2012 |
Lindgren HS, Dunnett SB. Cognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models? The European Journal of Neuroscience. 35: 1894-907. PMID 22708601 DOI: 10.1111/j.1460-9568.2012.08162.x |
0.393 |
|
| 2011 |
Lindgren HS, Rylander D, Iderberg H, Andersson M, O'Sullivan SS, Williams DR, Lees AJ, Cenci MA. Putaminal upregulation of FosB/ΔFosB-like immunoreactivity in Parkinson's disease patients with dyskinesia. Journal of Parkinson's Disease. 1: 347-57. PMID 23933656 DOI: 10.3233/Jpd-2011-11068 |
0.682 |
|
| 2011 |
Ohlin KE, Francardo V, Lindgren HS, Sillivan SE, O'Sullivan SS, Luksik AS, Vassoler FM, Lees AJ, Konradi C, Cenci MA. Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain : a Journal of Neurology. 134: 2339-57. PMID 21771855 DOI: 10.1093/Brain/Awr165 |
0.708 |
|
| 2011 |
Lindgren HS, Lane EL. Rodent lodels of l-DOPA-induced dyskinesia Neuromethods. 61: 337-351. DOI: 10.1007/978-1-61779-298-4_18 |
0.379 |
|
| 2010 |
Lindgren HS, Andersson DR, Lagerkvist S, Nissbrandt H, Cenci MA. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. Journal of Neurochemistry. 112: 1465-76. PMID 20050978 DOI: 10.1111/j.1471-4159.2009.06556.x |
0.393 |
|
| 2010 |
Lindgren HS, Angela Cenci M, Lane EL. Dyskinesia - Advances in the understanding of pathophysiology and possible treatment options European Neurological Review. 5: 34-40. DOI: 10.17925/Enr.2010.05.02.34 |
0.378 |
|
| 2009 |
Lindgren HS, Ohlin KE, Cenci MA. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 34: 2477-88. PMID 19606087 DOI: 10.1038/npp.2009.74 |
0.351 |
|
| 2008 |
Picconi B, Paillé V, Ghiglieri V, Bagetta V, Barone I, Lindgren HS, Bernardi G, Angela Cenci M, Calabresi P. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiology of Disease. 29: 327-35. PMID 17997101 DOI: 10.1016/j.nbd.2007.10.001 |
0.483 |
|
| 2007 |
Cenci M, Lindgren H. Advances in understanding l-DOPA-induced dyskinesia Current Opinion in Neurobiology. 17: 665-671. PMID 18308560 DOI: 10.1016/j.conb.2008.01.004 |
0.426 |
|
| 2007 |
Lindgren HS, Rylander D, Ohlin KE, Lundblad M, Cenci MA. The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behavioural Brain Research. 177: 150-9. PMID 17157933 DOI: 10.1016/J.Bbr.2006.09.019 |
0.743 |
|
| 2007 |
Valastro B, Andersson M, Lindgren HS, Cenci MA. Expression pattern of JunD after acute or chronic L-DOPA treatment: comparison with deltaFosB. Neuroscience. 144: 198-207. PMID 17055656 DOI: 10.1016/J.Neuroscience.2006.09.001 |
0.564 |
|
| 2007 |
Ohlin E, Lindgren H, Cenci M. 2.505 L-DOPA induces microvascular changes in the basal ganglia through the D1 receptor in a rat model of Parkinson's disease Parkinsonism & Related Disorders. 13: S143-S144. DOI: 10.1016/S1353-8020(08)70779-X |
0.379 |
|
| 2007 |
Andersson D, Lindgren H, Lagerkvist S, Cenci M, Nissbrandt H. 2.504 Monoamine neurotransmission in the rat model of L-DOPA-induced dyskinesia Parkinsonism & Related Disorders. 13: S143. DOI: 10.1016/S1353-8020(08)70778-8 |
0.373 |
|
| 2006 |
Westin JE, Lindgren HS, Gardi J, Nyengaard JR, Brundin P, Mohapel P, Cenci MA. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 9448-61. PMID 16971529 DOI: 10.1523/Jneurosci.0944-06.2006 |
0.62 |
|
| 2006 |
Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, Cenci MA. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. Journal of Neurochemistry. 96: 1718-27. PMID 16539687 DOI: 10.1111/J.1471-4159.2006.03696.X |
0.691 |
|
| 2004 |
Lundblad M, Picconi B, Lindgren H, Cenci MA. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiology of Disease. 16: 110-23. PMID 15207268 DOI: 10.1016/j.nbd.2004.01.007 |
0.685 |
|
| Show low-probability matches. |